CLOs on the Move

Altru Health System

www.altru.org

 
Altru Health System is a community-owned, integrated system with an acute care hospital, a specialty hospital, more than a dozen clinics in Grand Forks and the region, a large home care network, and a congregate living facility. It employs more than 200 physicians and 4,000 staff and has an annual net operating revenue of more than $450 million. As the first member of the Mayo Clinic Care Network, Altru’s providers have access to clinically integrated tools extending Mayo Clinic’s knowledge and expertise to patients.
  • Number of Employees: 1K-5K
  • Annual Revenue: $250-500 Million
  • www.altru.org
  • P.O. Box 6002
    Grand Forks, ND USA 58206
  • Phone: 701.780.5000

Executives

Name Title Contact Details

Similar Companies

Themis Vision Systems

Themis Vision Systems is a Stennis Space Center, MS-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Certified Laboratories

Certified Laboratories is a Plainview, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Sturgis Hospital

Sturgis Hospital is one of the leading providers in Healthcare, Pharmaceuticals, & Biotech. It is based in Sturgis, MI. To find more information about Sturgis Hospital, please visit www.sturgishospital.com

Retreat Behavioral Health

Retreat Behavioral Health is a provider of substance use disorder and mental health treatment services with locations along the East Coast. Their goal is to help people easily access the best quality of care in a holistic and peaceful environment.

Alnylam

Alnylam is the world`s leading RNAi therapeutics company and the first and only company to bring an RNAi medicine to market. We are developing RNAi (RNA interference) as an innovative, entirely new class of medicines to treat rare genetic, cardio metabolic, acute hepatic infectious and central nervous system (CNS) and ocular diseases. Alnylam was founded in 2002 based on a Nobel Prize-winning breakthrough in biology – the discovery of RNAi, and a bold vision that this discovery could be used to silence disease-causing genes upstream of today`s medicines. We are relentless in our pursuit of new treatments because we believe that RNAi therapeutics can be used to treat many diseases for which treatment options do not exist or are inadequate. Overall, we believe that patients shouldn`t have to wait for hope. Alnylam is turning scientific possibility into reality - in 2018, the FDA and European EMA approved of our first product, ONPATTRO (patisiran) which is also the first-ever approved RNAi therapeutic. In 2019, the FDA approved our second product, GIVLAARI (givosiran). Our robust pipeline of investigational medicines includes multiple programs in late-stage and early-stage clinical development. We are a global and diverse company of more than 1,500 people. We pride ourself on fostering a fun, inclusive and dynamic work environment where employees can recognize their fullest potential. That`s why we`ve been named a Science Magazine Top Employer for two years in a row (`19-`20), a Boston Globe Top Place to Work 5x in a row (`15-`19) and one of Fast Company`s 50 Most Innovative Companies for 2019. We are based in Cambridge, U.S., with offices throughout Europe, Asia and South America.